FDA declines to approve Cosmo’s NDA for Methylene Blue MMX
The CRL is consistent with the preliminary feedback Cosmo announced on May 9, 2018, stating that the FDA identified unspecified deficiencies that preclude the continuation of the discussion
AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.
The patents, among other aspects, broadly cover compositions of matter of the inflammation-targeting microfiber materials with embedded molecules of interest. The platform is being evaluated for use across